Spondyloperipheral dysplasia-short ulna syndrome

Spondyloperipheral dysplasia-short ulna syndrome (also known as spondyloperipheral dysplasia) is an extremely rare genetic skeletal disorder classified among the type II collagenopathies. It is caused by mutations in the COL2A1 gene, which encodes type II collagen, a critical structural protein in cartilage, the vitreous of the eye, and intervertebral discs. The condition primarily affects the skeletal system, with characteristic features including platyspondyly (flattened vertebral bodies), shortening of the long bones particularly the ulna, brachydactyly (short fingers and toes), and other peripheral skeletal anomalies. Patients may also exhibit short stature and limb length discrepancies. As a type II collagenopathy, spondyloperipheral dysplasia shares features with other disorders in this spectrum, such as spondyloepiphyseal dysplasia and Kniest dysplasia, but is distinguished by its particular combination of spinal and peripheral skeletal involvement, especially the characteristic short ulna. Some patients may also have mild ocular findings, consistent with the role of type II collagen in the eye. The condition is typically recognized in childhood based on radiographic findings and clinical examination. There is currently no cure or disease-specific treatment for spondyloperipheral dysplasia-short ulna syndrome. Management is supportive and symptomatic, focusing on orthopedic monitoring and intervention as needed, pain management, and surveillance for potential complications. Genetic counseling is recommended for affected individuals and their families. Due to the extreme rarity of this condition, clinical experience is limited and largely based on individual case reports.

Common questions about Spondyloperipheral dysplasia-short ulna syndrome